These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 26241852

  • 1. Comparison of Outcomes and Costs of Ranibizumab and Aflibercept Treatment in Real-Life.
    Schmid MK, Reich O, Faes L, Boehni SC, Bittner M, Howell JP, Thiel MA, Signorell A, Bachmann LM.
    PLoS One; 2015; 10(8):e0135050. PubMed ID: 26241852
    [Abstract] [Full Text] [Related]

  • 2. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS, Bressler NM, Avery RL, Bakri SJ, Boyer DS, Brown DM, Dugel PU, Freund KB, Glassman AR, Kim JE, Martin DF, Pollack JS, Regillo CD, Rosenfeld PJ, Schachat AP, Wells JA, American Society of Retina Specialists Anti-VEGF for Diabetic Macular Edema Comparative Effectiveness Panel.
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [Abstract] [Full Text] [Related]

  • 3. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B, Thomas SM, Lillie E, Lee T, Hamid J, Richter T, Janoudi G, Agarwal A, Sharpe JP, Scott A, Warren R, Brahmbhatt R, Macdonald E, Straus SE, Tricco AC.
    BMJ Open; 2019 May 28; 9(5):e022031. PubMed ID: 31142516
    [Abstract] [Full Text] [Related]

  • 4. Outcomes and costs of Ranibizumab and Aflibercept treatment in a health-service research context.
    Schmid MK, Reich O, Blozik E, Faes L, Bodmer NS, Locher S, Thiel MA, Rapold R, Kuhn M, Bachmann LM.
    BMC Ophthalmol; 2018 Feb 27; 18(1):64. PubMed ID: 29486762
    [Abstract] [Full Text] [Related]

  • 5. Cost-Effectiveness of Ranibizumab Versus Aflibercept for Macular Edema Secondary to Branch Retinal Vein Occlusion: A UK Healthcare Perspective.
    Adedokun L, Burke C.
    Adv Ther; 2016 Jan 27; 33(1):116-28. PubMed ID: 26747252
    [Abstract] [Full Text] [Related]

  • 6. Clinical outcome after switching therapy from ranibizumab and/or bevacizumab to aflibercept in central retinal vein occlusion.
    Pfau M, Fassnacht-Riederle H, Becker MD, Graf N, Michels S.
    Ophthalmic Res; 2015 Jan 27; 54(3):150-6. PubMed ID: 26413794
    [Abstract] [Full Text] [Related]

  • 7. Real-World Injection Frequency and Cost of Ranibizumab and Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
    Kiss S, Malangone-Monaco E, Wilson K, Varker H, Stetsovsky D, Smith D, Garmo V.
    J Manag Care Spec Pharm; 2020 Mar 27; 26(3):253-266. PubMed ID: 32020843
    [Abstract] [Full Text] [Related]

  • 8. Ziv-aflibercept in macular disease.
    Mansour AM, Al-Ghadban SI, Yunis MH, El-Sabban ME.
    Br J Ophthalmol; 2015 Aug 27; 99(8):1055-9. PubMed ID: 25677668
    [Abstract] [Full Text] [Related]

  • 9. Healthcare resource use and costs of diabetic macular oedema for patients with antivascular endothelial growth factor versus a dexamethasone intravitreal implant in Korea: a population-based study.
    Cho H, Choi KS, Lee JY, Lee D, Choi NK, Lee Y, Bae S.
    BMJ Open; 2019 Sep 20; 9(9):e030930. PubMed ID: 31542758
    [Abstract] [Full Text] [Related]

  • 10. Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV.
    Wecker T, Ehlken C, Bühler A, Lange C, Agostini H, Böhringer D, Stahl A.
    Br J Ophthalmol; 2017 Mar 20; 101(3):353-359. PubMed ID: 27215744
    [Abstract] [Full Text] [Related]

  • 11. Aflibercept: an update on recent milestones achieved.
    Palejwala NV, Lauer AK.
    Drugs Today (Barc); 2014 Dec 20; 50(12):779-90. PubMed ID: 25588083
    [Abstract] [Full Text] [Related]

  • 12. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.
    Parikh R, Ross JS, Sangaralingham LR, Adelman RA, Shah ND, Barkmeier AJ.
    Ophthalmology; 2017 Mar 20; 124(3):352-358. PubMed ID: 27890437
    [Abstract] [Full Text] [Related]

  • 13. The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.
    Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A.
    Klin Monbl Augenheilkd; 2015 Apr 20; 232(4):552-5. PubMed ID: 25902119
    [Abstract] [Full Text] [Related]

  • 14. Aflibercept in the treatment of neovascular age-related macular degeneration in previously treated patients.
    Hall LB, Zebardast N, Huang JJ, Adelman RA.
    J Ocul Pharmacol Ther; 2014 May 20; 30(4):346-52. PubMed ID: 24552305
    [Abstract] [Full Text] [Related]

  • 15. Patterns of ranibizumab and aflibercept treatment of central retinal vein occlusion in routine clinical practice in the USA.
    Lotery AJ, Regnier S.
    Eye (Lond); 2015 Mar 20; 29(3):380-7. PubMed ID: 25572584
    [Abstract] [Full Text] [Related]

  • 16. Cost and Selection of Ophthalmic Anti-Vascular Endothelial Growth Factor Agents.
    Li E, Greenberg PB, Voruganti I, Krzystolik MG.
    R I Med J (2013); 2016 May 02; 99(5):15-7. PubMed ID: 27128510
    [Abstract] [Full Text] [Related]

  • 17. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
    Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P.
    Ophthalmology; 2012 Apr 02; 119(4):802-9. PubMed ID: 22301066
    [Abstract] [Full Text] [Related]

  • 18. Functional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatment.
    Gerding H.
    Klin Monbl Augenheilkd; 2015 Apr 02; 232(4):560-3. PubMed ID: 25902122
    [Abstract] [Full Text] [Related]

  • 19. Injections frequency and health care costs in patients treated with aflibercept compared to ranibizumab: new real-life evidence from Switzerland.
    Reich O, Schmid MK, Rapold R, Bachmann LM, Blozik E.
    BMC Ophthalmol; 2017 Dec 04; 17(1):234. PubMed ID: 29202760
    [Abstract] [Full Text] [Related]

  • 20. Treatment patterns in patients with age-related macular degeneration and diabetic macular edema: A real-world claims analysis in Dubai.
    Kozak I, Gurbaxani A, Safar A, Rao P, Masalmeh A, Assaf H, Farghaly M, Pathak P, Natarajan A, Saffar I.
    PLoS One; 2021 Dec 04; 16(7):e0254569. PubMed ID: 34255798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.